Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck

Seminars in Oncology

Volumn 31, Issue 6, 2004, Pages 809-815

  Fanucchi, Michael ^a   Khuri, Fadlo R ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DIHYDROFOLATE REDUCTASE; DOCETAXEL; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLIC ACID ANTAGONIST; GEFITINIB; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; NAVELBINE; NUCLEOSIDE ANALOG; ONYX 015; OXALIPLATIN; PACLITAXEL; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PLATINUM; PLATINUM DERIVATIVE; PROTEIN P53; RALTITREXED; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE INHIBITOR; UNINDEXED DRUG;

ANALGESIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DRUG TOLERANCE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HUMAN; HYPOMAGNESEMIA; HYPOTENSION; METASTASIS; NEUROPATHY; NEUTROPENIA; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 10044289589     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.09.014     Document Type: Article

References (61)

1. A. Jemal, R.C. Tiwari, T. Murray Cancer statistics CA Cancer J Clin 54 2004 8 29
2. B. Brockstein, D. Haraf, M. Kies Survival, patterns of failure, and risk factors for recurrence after intensive concomitant chemoradiation (CRT) for squamous cell head and neck cancer (SCHNC) Proc Am Soc Clin Oncol 21 2002 918A (abstr)
3. X. Leon, R. Hitt, M. Constenia A retrospective analysis of the outcome of patients with recurrent or metastatic squamous cell carcinoma of the head and neck who are progressing on platinum-based palliative chemotherapy Proc Am Soc Clin Oncol 22 2003 502 (abstr 2022)
4. A.S. Planting, G. Catimel, P.H. de Mulder EORTC Head and Neck Cooperative Group Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer Ann Oncol 10 1999 693 700
5. C. Jacobs, G. Lyman, E. Velez-Garcia A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck J Clin Oncol 10 1992 257 263
6. A.A. Forastiere, B. Metch, D.E. Schuller Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck A Southwest Oncology Group study J Clin Oncol 10 1992 1245 1251
7. F.R. Khuri, D.M. Shin, B.S. Glisson Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck Current status and future directions Semin Oncol 27 2000 25 33
8. A. Forastiere, W. Koch, A. Trotti Head and neck cancer N Engl J Med 345 2001 1890 1900
9. E.S. Kim, B.S. Glisson Treatment of metastatic head and neck cancer Chemotherapy and novel agents Cancer Treat Res 114 2003 295 314
10. X. Pivot, E. Chamorey, E. Guardiola, N. Magne Phase I and pharmacokinetic study of the association of capecitabine-cisplatin ih head and neck cancer patients Ann Oncol 14 2003 1578 1586
11. A.A. Forastiere Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck Semin Oncol 20 1993 56 60
12. G. Catimel, J. Verweij, V. Mattijssen EORTC Early Clinical Trials Group Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 1994 533 537
13. A. Forastiere, T. Leong, E. Rowinsky Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer Eastern Co-operative Oncology Group Study E1393 J Clin Oncol 19 2001 1088 1095
14. (abstr) B. Murphy, Y. Li, D. Cella Phase III study comparing cisplatin and 5-flurouracil versus cisplatin and paclitaxel in metastatic/recurrent head and neck cancer Proc Am Soc Clin Oncol 20 2001 224a
15. (abstr) N. Wells, B. Murphy, M. Dietrich Quality of life and pain assessment for head and neck cancer patients treated on E1395 A comparison of two different cisplatin-based chemotherapy regimens Proc Am Soc Clin Oncol 21228A 2002
16. B. Glisson, B. Murphy, G. Frenette Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck J Clin Oncol 20 2002 1593 1599
17. L. Specht, S. Larsen, H. Hansen Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck Ann Oncol 11 2000 845 849
18. P. Schoffski, G. Catimel, A.S. Planting Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group Ann Oncol 10 1999 119 122
19. G. Fountzilas, D. Skarlos, A. Athanassiades Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group Ann Oncol 8 1997 451 455
20. X. Pivot, L. Cals, D. Cupissol Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck Oncology 60 2001 66 71
21. (abstr) M. Schroeder, M. Holzgraefe Docetaxel-carboplatin for palliative chemotherapy in recurrent head and neck cancer Proc Am Soc Clin Oncol 22508a 2003
22. M. Degardin, P. Cappelaere, I. Krakowski Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck Eur J Cancer B Oral Oncol 32B 1996 278 279 (abstr)
23. M. Debled, R. Gervais, B. Laguerre Phase II study of oxaliplatin in combination with 5-fluorouracil in first line treatment of locally advanced or metastatic squamous cell carcinoma of the head and neck Proc Am Soc Clin Oncol 22 2003 509a
24. D.M. Shin, B.S. Glisson, F.R. Khuri Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck Semin Oncol 25 1998 40 48
25. D.M. Shin, F.R. Khuri, B.S. Glisson Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma Cancer 91 2001 1316 1323
26. J. Janinis, M. Papadakou, E. Xidakis Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer A phase II feasibility study Am J Clin Oncol 23 2000 128 131
27. G. Catimel, J.B. Vermorken, M. Clavel EORTC Early Clinical Trials Group A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 1994 543 547
28. W.E. Samlowski, H. Gundacker, J.P. Kuebler Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck A Southwest Oncology Group phase II study Invest New Drugs 19 2001 311 315
29. R. Hitt, D. Castellano, M. Hidalgo Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck Ann Oncol 9 1998 1347 1349
30. B.B. Ma, I.F. Tannock, G.R. Pond Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma Cancer 95 2002 2516 2523
31. R.K. Ngan, H.H. Yiu, W.H. Lau Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma Report of a phase II study Ann Oncol 13 2002 1252 1258
32. M. Degardin, J. Oliveira, L. Geoffrois An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck Ann Oncol 9 1998 1103 1107
33. A. Testolin, G. Recher, V. Cristoferi Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma. A phase II study Invest New Drugs 12 1994 231 234
34. S. Saxman, B. Mann, V. Canfield A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck Am J Clin Oncol 21 1998 398 400
35. E. Espinosa, P. Zamora, A. Milla A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck Head Neck 24 2002 1054 1059
36. V. Gebbia, A. Testa, C. Di Gregorio Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck Am J Clin Oncol 18 1995 293 296
37. V. Gebbia, G. Mantovani, B. Agostara Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil A multicenter phase II trial Ann Oncol 6 1995 987 991
38. X. Pivot, E. Raymond, B. Laguerre Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck Br J Cancer 85 2001 649 655
39. X. Pivot, S. Wadler, C. Kelly Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer Ann Oncol 12 2001 1595 1599
40. W.E. Samlowski, D. Lew, P.J. Kuebler Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck A Southwest Oncology Group study Invest New Drugs 16 1998 271 274
41. M. Moroni, L. Giannetta, G. Gelosa Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated with a cisplatin-containing regimen A phase II study J Chemother 15 2003 394 399
42. (abstr) D. Cupissol, G. Calais, J. Tourani Phase II study of docetaxel plus gemcitabine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck Proc Am Soc Clin Oncol 22 2003 508a
43. M. Airoldi, L. Cattel, S. Marchionatti Docetaxel and vinorelbine in recurrent head and neck cancer Pharmacokinetic and clinical results Am J Clin Oncol 26 2003 378 381
44. M. Airoldi, L. Cattel, G. Cortesina Gemcitabine and vinorelbine in recurrent head and neck cancer Pharmacokinetic and clinical results Anticancer Res 23 2003 2845 2852
45. J. Bischoff, D. Kim, A. Williams An adenovirus mutant that replicates selectively in p53-deficient tumor cells Science 274 1996 373 376
46. C. Heise, A. Sampson-Johannes, A. Williams ONYX-015, an E1B gene- attenuated virus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Nat Med 3 1997 639 645
47. J. Nemunaitis, F.R. Khuri, I. Ganly Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer J Clin Oncol 19 2001 289 298
48. I. Ganly, S. Eckhardt, G. Rodriquez A phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 2000 798 806
49. F.R. Khuri, J. Nemunaitis, I. Ganly A controlled trial of intratumoral ONYX- 015, a selectively-replicating adenovirus, in combination with cisplatin and 5- fluorouracil in patients with recurrent head and neck cancer Nat Med 6 2000 879 885
50. Y. Horio, Y. Hasegawa, Y. Sekido Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells Cancer Gene Ther 7 2000 537 544
51. G. Clayman, A. El-Naggar, S.M. Lippman Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma J Clin Oncol 16 1998 2221 2232
52. J. Nemunaitis, C. Cunningham, A. Buchanan Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients Gene Ther 8 2001 746 759
53. R. Herbst, D. Shin Monoclonal antibodies to target epidermal growth factor receptor-positive tumors Cancer 94 2002 1593 1611
54. E. Cohen, F. Rosen, A. Dekker Phase II trial of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 21 2003 1980 1987
55. E. Cohen, K. Stenson, D. Gustin A phase II study of of 250 mg gefitinib (ZD1839) monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) Proc Am Soc Clin Oncol 22 2003 502 (abstr 2021)
56. D.M. Shin, N. Donato, M. Cooper Epidermal growth factor receptor targeted therapy with humanized chimeric monoclonal antibody, C225, in combination with cisplatin in patients with head and neck cancer Clin Cancer Res 7 2001 1204 1213
57. M. Kies, M. Arquette, L. Nabell Final report of the efficacy and safety of the anti-epidermal growth factor antibody Eribitux (IMC-225) in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy Proc Am Soc Clin Oncol 21 2002 232A (abstr)
58. J. Baselga, J. Trigo, J. Bourhis Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen Proc Am Soc Clin Oncol 21 2002 226A (abstr)
59. B. Burtness, Y. Li, W. Flood Phase III study comparing cisplatin + placebo to cisplatin + anti-epidermal growth factor antibody C225 in patients with metastatic/recurrent head and neck cancer Proc Am Soc Clin Oncol 21 2002 226A (abstr)
60. M. Kies, G.L. Clayman, A.K. El-Naggar Induction therapy with SCH 6636, a farnesyl transferase inhibitor, in squamous cell carcinoma of the head and neck Proc Am Soc Clin Oncol 20 2001 896a (abstr)
61. E.E. Cohen, F. Rosen, W.M. Stadler Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 21 2003 1980 1987